The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Prostate Cancer
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
-
Mayo Clinic Arizona, Scottsdale, Arizona, United States, 85259
St. Joseph Hospital, Orange, California, United States, 92686
Providence Saint Johns Health Ctr, Santa Monica, California, United States, 90404
University of Colorado, Aurora, Colorado, United States, 80045
Hartford Hospital, Hartford, Connecticut, United States, 06102
VA Medical Center, Washington, District of Columbia, United States, 20422
Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224
University Cancer and Blood Center LLC, Athens, Georgia, United States, 30607
Parkview Research Center, Fort Wayne, Indiana, United States, 46845
Tulane Cancer Center, New Orleans, Louisiana, United States, 70112
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 100 Years
MALE
No
Novartis Pharmaceuticals,
Novartis Pharmaceuticals, STUDY_DIRECTOR, Novartis Pharmaceuticals
2033-07-21